Global Multiple Myeloma Drugs Market 2015-2019: Key Vendors are Celgene, Johnson & Johnson, Novartis, Onyx Pharmaceuticals, Sanofi and Takeda Pharmaceutical
DUBLIN, Jan. 29, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/6phb2m/global_multiple) has announced the addition of the "Global Multiple Myeloma Drugs Market 2015-2019" report to their offering.
Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors.
Myeloma occurs when the malignant cells form a tumor. According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight.
The disease can be diagnosed by a series of tests. The initial evaluation consists of a blood test, urine test and a bone marrow biopsy. X-ray, MRI scan, CT- scan and PET scan are other tests to diagnose multiple myeloma. Genomic testing is also carried out to confirm the presence of multiple myeloma in the suspected patients.
The analysts forecast the Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
One of the major trends being witnessed in this market is increased awareness about multiple myeloma among the medical fraternity, patients, and the families of patients, which enhances the number of treatment-seeking patients, which results in an increase in the overall consumption of medicines.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disease Overview
08. Market Landscape
09. Market Segmentation by Route of Administration
10. Market Segmentation by Dosage Form
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Pipeline Portfolio
20. Vendor Landscape
21. Key Vendor Analysis
22. Other Reports in this Series
Companies Mentioned:
- AB Science
- Abbvie
- Aeterna Zentaris
- Amgen
- Bristol Myers Squibb
- Celgene
- Cephalon
- Daiichi Sankyo
- Genta
- Johnson & Johnson
- Merck Sharp and Dohme
- Novartis
- Oncotherapeutics
- Onyx Pharmaceuticals
- PharmaMar
- Sanofi
- Takeda Pharmaceutical
- Teva
For more information visit http://www.researchandmarkets.com/research/6phb2m/global_multiple
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article